Cambridge Startup's Inhaler Tech Can Tackle Lung Problems

Cambridge startup's inhaler tech can tackle lung problems

A startup designing and licensing inhaler technology has announced Quattrii – the first ever dry powder inhaler (DPI) engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation.  Cambridge Healthcare Innovations (CHI) has designed Quattrii in an attempt to transform the delivery of drugs for conditions that affect the lungs and airways and the engine will be available for pharmaceutical companies to start us…

First of its kind inhaler for conditions beyond asthma and COPD to reshape respiratory drug delivery

Cambridge-based start-up rolls out industry-first inhaler for delivering large amounts of drug in a single inhalation, enabling next-gen inhaled biologics for novel therapies CAMBRIDGE, 24 June 2025: Cambridge Healthcare Innovations (CHI), a start-up designing and licensing revolutionary inhaler technology, today announced Quattrii, the first ever dry powder inhaler (DPI) engine that is capable of delivering large volumes of biologic and mRNA mo…

"First of its kind" inhaler for conditions beyond asthma and COPD

Cambridge Healthcare Innovations (CHI), has announced Quattrii, the first ever dry powder inhaler (DPI) engine that is capable of delivering large volumes of biologic and mRNA molecules in a single inhalation.